RD

Rosamond Deegan

CEO

OMass Therapeutics

Oxford, England


Contact Information

Email
Unlock
LinkedIn

Company Information

Company
OMass Therapeutics
Industry
research
Employees
87.0
Seniority
C suite
Annual Revenue
503000.0
Total Funding
159256061.0
Latest Funding
Series B

Technologies

ElasticEmail Outlook MailChimp SPF Microsoft Office 365 DigitalOcean Cloudways Workable reCAPTCHA Nginx MailChimp New Relic Google Maps (Non Paid Users) Google Analytics YouTube Mobile Friendly Google Maps WordPress.org Google Font API Google Tag Manager Remote

Keywords

biotechnology research biotechnology drug discovery native mass spectrometry biochemistry orphan diseases immunological diseases soluble carriers gpcrs inflammasome complexes small molecule therapeutics membrane proteins cell-free methods drug interaction binding affinity therapeutic development therapeutic innovation patient-centered treatments target ecosystems clinical candidates high-resolution analysis biopharmaceuticals genetic association pathway linked patient selection high unmet need lead optimization pharmacology bioscience regulatory pathways drug targets innovative therapies biomolecule interactions bioengineering molecular pharmacology translational medicine precision medicine high fidelity measurements differentiated therapies drug efficacy structural biology multi-modal drug approaches therapeutics pipeline academic partnership science-driven venture capital protein complexes therapeutic candidates strategic investments cro therapeutic engineering biopharma collaboration

Get Full Contact Details

Subscribe to reveal email addresses and export contacts.

View Plans